How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/copd-associated-with-chronic-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

COPD Associated with Chronic Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COPD Associated with Chronic Bronchitis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating COPD Associated with Chronic Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Daliresp	ROFLUMILAST	Arcutis	Phosphodiesterase 4 Inhibitor [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	2011-01-01
Foradil	FORMOTEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Serevent	Serevent	Fundacio Privada Mon Clinic Barcelona		Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Aminophyllin	Aminophyllin	University of Padova		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1
Flixotide	Flixotide	Mundipharma Research Limited		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Fluticason	Fluticason	Creighton University		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Theophyllin	Theophyllin	University of Bergen		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1
Daxas	Daxas	AstraZeneca		cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Arcutis · 1 drug in COPD Associated with Chronic Bronchitis
AstraZeneca · 1 drug in COPD Associated with Chronic Bronchitis
Creighton University · 1 drug in COPD Associated with Chronic Bronchitis
Fundacio Privada Mon Clinic Barcelona · 1 drug in COPD Associated with Chronic Bronchitis
GSK (GlaxoSmithKline) · 1 drug in COPD Associated with Chronic Bronchitis
Mundipharma Research Limited · 1 drug in COPD Associated with Chronic Bronchitis
Novartis · 1 drug in COPD Associated with Chronic Bronchitis
Teva Pharm · 1 drug in COPD Associated with Chronic Bronchitis
University of Bergen · 1 drug in COPD Associated with Chronic Bronchitis
University of Padova · 1 drug in COPD Associated with Chronic Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in COPD Associated with Chronic Bronchitis:

Cite this brief

Drug Landscape (2026). COPD Associated with Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/copd-associated-with-chronic-bronchitis. Accessed 2026-06-10.

COPD Associated with Chronic Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing